DISCLAIMER: This page is intended for members of the general public in Luxembourg only.
The information provided on this site is intended for general information and education for Luxembourg-based members of the public and is not intended to be a substitute for the advice provided by a physician or other qualified healthcare professional.
Information about the NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) (also known as NVX-CoV2373)
NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) has been granted a conditional marketing authorisation for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
For more information about the NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted), download the Package Leaflet.
Report an Adverse Event (AE)
If you are concerned about any potential side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the Package Leaflet.
Either you or your healthcare professional can report any suspected adverse reactions via the national reporting system of Luxembourg.
Centre Régional de Pharmacovigilance de Nancy
Bâtiment de Biologie Moléculaire et de Biopathologie (BBB)
CHRU de Nancy – Hôpitaux de Brabois
Rue du Morvan
54 511 VANDOEUVRE LES NANCY CEDEX
Tél: (+33) 3 83 65 60 85 / 87
e-mail: [email protected]
Link to the notification form: www.guichet.public.lu/fr/entreprises/sectoriel/sante/medecins/notification-effets-indesirables-medicaments.html
Tel: +352 20 33 17 08
09:00 - 17:00
Monday - Friday